论文部分内容阅读
目的探讨胃癌组织中KAI1/CD82、MRP1/CD9的表达及临床意义。方法应用免疫组化SABC法检测63例胃癌组织中KAI1/CD82、MRP1/CD9的表达,分析其与临床病理特征的关系。结果胃癌组织KAI1/CD82的阳性表达率为63.5%(40/63)、MRP1/CD9的阳性表达率为46.0%(29/63)。KAI1/CD82的表达与淋巴结转移、肿瘤分级、癌组织大小显著相关(P<0.05)。MRP1/CD9的表达与淋巴结转移、肿瘤分级显著相关(P<0.05或P<0.01)。结论 KAI1/CD82和MRP1/CD9可作为评估胃癌预后的指标。
Objective To investigate the expression and clinical significance of KAI1 / CD82 and MRP1 / CD9 in gastric cancer. Methods The expressions of KAI1 / CD82 and MRP1 / CD9 in 63 cases of gastric cancer were detected by immunohistochemical SABC method. The relationship between KAI1 / CD82 and MRP1 / CD9 was analyzed. Results The positive rates of KAI1 / CD82 in gastric cancer tissues were 63.5% (40/63) and 46.0% (29/63) in MRP1 / CD9 specimens. The expression of KAI1 / CD82 was significantly associated with lymph node metastasis, tumor grade and tumor size (P <0.05). The expression of MRP1 / CD9 was significantly associated with lymph node metastasis and tumor grade (P <0.05 or P <0.01). Conclusion KAI1 / CD82 and MRP1 / CD9 can be used as an index to evaluate the prognosis of gastric cancer.